The hypothesis that prolactin, a hormone dependent on hypothalamic dopamine activity, might be implicated in mental illness was first introduced by Horrobin et al.1 Their suggestion that abnormal concentrations of prolactin were specifically involved in affective disorders responsive to lithium was soon followed by a clinical report2 on the use of bromocriptine, a dopamine-receptor sensitiser and prolactin suppressor, in two patients with severe mania in whom phenothiazines and lithium were contraindicated. A dramatic recovery within 10 days was reported. The availability of a potentially useful drug in mania based on a new approach to the possible aetiology of affective disorders prompted the present study.
Patients, methods, and results
Women inpatients diagnosed independently by two psychiatrists as suffering from manic depressive psychosis-manic type (ICD 296-1)-were admitted to the trial and were prescribed nitrazepam 5 mg thrice daily and 10 mg at night. They were randomly assigned to two groups, one receiving bromocriptine 2-5 mg thrice daily increased to 5 mg thrice daily after three days, the other an identical placebo. Nursing staff rated the patients daily on a simple seven-point rating scale for severity of illness and two psychiatrists rated the patients on days 1 and 7 using an analogue line for severity of illness. Sleep was estimated by half-hourly observation throughout the night and any side effects were noted on a comprehensive checklist. Temperature, pulse and respiration rates, and blood pressure were recorded daily. A fasting blood sample for measuring prolactin concentration was taken at 9 am before taking the drugs on day 1 of the trial and under the same conditions on the day after the trial was completed (that is, 11 hours after the last dose of drug). Twenty out of 23 patients entering the trial completed it. Three were withdrawn because of severity of symptoms (two on placebo and one on bromocriptine). Ten patients (mean ± SE of mean age 55 + 16 years) completed seven days' treatment with placebo and 10 (mean age 52± 10 years) completed seven days' treatment with bromocriptine. The ages of the patients in the two groups were not significantly different (t= 0-58). At no time during the trial was there any significant difference between the groups when assessed on either the nurses' daily ratings or the psychiatrists' ratings (table) using the Mann-Whitney test.
Comparison of severity of manic depressive illness over seven days in 10 patients treated with placebo and 10 treated with bromocriptine as rated daily by nursing staff and on days 1 and 7 by medical staff on analogue line 
.NS NS NS NS NS NS NS NS NS
NS = not significant.
Similarly, there was no significant difference between the sleep of the two groups. Patients on placebo slept for an average of 6-1+1-7 hours on the first night of the trial and had a mean nightly sleep of 5-6+ 1-3 hours over the week. The patients receiving bromocriptine slept for a mean of 5-4+ 2-3 hours on the first night of the trial and had a mean nightly sleep of 5-2+1-3 hours over the week of the trial (first night t=0-63 (NS), mean nightly sleep t=0-59 (NS)). Ratings were completed for 8 patients in each group. No side effects were noted which could be attributed to the active drug. Blood samples for serum prolactin measurement were taken from eight patients in the placebo group and six in the active group. The prolactin concentrations for the placebo group were 576 mU/l (range 163-1475 mU/l) and 447 mU/1 (range 44-2000 mU/1) (sign test NS). The concentrations for the active group were 835 mU/1 (range 91-1900 mU/l) and 72 mU/l (range 42-133 mU/l) (sign test P=0-016).
Comment
In this study bromocriptine had no demonstrable effect in mania. The dose was the same as that reported to be therapeutic,2 and the fall in prolactin concentrations suggest that the drug was exerting its effect as a dopamine agonist. In neither the daily nurse ratings nor the medical-staff ratings was there any significant difference between the placebo and the active groups, nor was there any difference in sleep pattern. The results of this trial cast doubt on the hypothesis that prolactin concentrations and hypothalamic dopamine activity are important in manic depressive illness.
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